CDK4 and neoplasm: Although combination therapies are typically administered simultaneously, the “priming strategy” using CDK4/6 inhibitors—short‐term pretreatment to synchronize tumor cell cycles and enhance sensitivity to subsequent therapies—has emerged as a focus in HNSCC clinical research.